Michael Morrissey, Exelixis CEO
Exelixis shells out $100M cash in a pair of deals, shooting for different takes on CD47, ADCs
Now that its cabozantinib franchise — including Cabometyx tablets and Cometriq capsules — has nestled its way into blockbuster status, Exelixis is replenishing the pipeline with some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.